William Blair Comments on PTC Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:PTCT)
PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) – William Blair raised their Q2 2024 EPS estimates for shares of PTC Therapeutics in a research report issued on Monday, May 20th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will post earnings of ($0.67) per share for the quarter, up from their previous […]
More Stories
Oshkosh Co. (NYSE:OSK) Receives $125.79 Consensus PT from Analysts
Shares of Oshkosh Co. (NYSE:OSK – Get Free Report) have been given an average rating of “Hold” by the fourteen...
Redeia Corporación (OTCMKTS:RDEIY) versus Barratt Developments (OTCMKTS:BTDPY) Head-To-Head Review
Barratt Developments (OTCMKTS:BTDPY – Get Free Report) and Redeia Corporación (OTCMKTS:RDEIY – Get Free Report) are both finance companies, but...
Analyzing Lithia Motors (NYSE:LAD) & D’Ieteren Group (OTCMKTS:SIEVF)
Lithia Motors (NYSE:LAD – Get Free Report) and D’Ieteren Group (OTCMKTS:SIEVF – Get Free Report) are both retail/wholesale companies, but...
Short Interest in T Stamp Inc. (NASDAQ:IDAI) Increases By 57.5%
T Stamp Inc. (NASDAQ:IDAI – Get Free Report) was the recipient of a large growth in short interest in the...
Short Interest in InMed Pharmaceuticals Inc. (NASDAQ:INM) Expands By 55.3%
InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) was the recipient of a large increase in short interest during the...
Barclays Increases Cintas (NASDAQ:CTAS) Price Target to $245.00
Cintas (NASDAQ:CTAS – Get Free Report) had its target price upped by Barclays from $210.00 to $245.00 in a research...